ArticleCNS neuroscience & therapeutics2026
Glymphatic Dysfunction in Children With Type 2 and 3 Spinal Muscular Atrophy.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSpinal muscular atrophy (SMA) not only causes lower motor neuron degeneration but also affects brain development. Given the role of the glymphatic system in maintaining brain homeostasis during development, this study explores glymphatic changes in children with type 2 and 3 SMA.
methodsForty-eight children with SMA and 53 age- and sex-matched typically developing (TD) controls were prospectively recruited. A subgroup of 22 patients received nusinersen for one year. Glymphatic function was measured using diffusion tensor image analysis along the perivascular space (DTI-ALPS) index, frequency of enlarged perivascular space (ePVS), and the coupling strength of global blood-oxygen-level-dependent (gBOLD) signals and cerebrospinal fluid (CSF) dynamics. Based on the data distribution, these parameters were compared using a two-sample t-test or Mann-Whitney U test, followed by False Discovery Rate (FDR) correction. Partial correlation analysis examined the associations between these parameters and clinical severity.
resultsCompared to TD children, SMA children exhibited increased CSF volume, higher ePVS frequency, and a lower ALPS index. CSF volume was negatively correlated with SMA severity. Post-treatment SMA patients showed increased CSF and a lower ALPS index.
conclusionsThis study revealed glymphatic dysfunction in SMA and its correlation with clinical severity, highlighting a previously unrecognized feature of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.